Chemomab Therapeutics Ltd.
Datakwaliteit: 83%
CMMB
Nasdaq
Manufacturing
Chemicals
€ 1,67
€ 0,00
(0,00%)
Marktkapitalisatie: 12,13 M
Prijs
€ 1,69
Marktkapitalisatie
12,13 M
Dagbereik
—
52-Weeksbereik
—
Volume
—
Openen —
50D / 200D Gem.
—
50D / 200D Gem.
—
Quick Summary
Belangrijkste Punten
Negative free cash flow of -11,13 M
Groei
Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A
Kwaliteit
Return on Equity
-91,39%
Onder sectorgemiddelde (-53,41%)
ROIC-887,68%
Net MarginN/A
Op. MarginN/A
Veiligheid
Debt / Equity
N/A
Current Ratio7,42
Interest CoverageN/A
Waardering
PE (TTM)
-1,35
Boven sectorgemiddelde (-1,48)
P/B Ratio1,25
EV/EBITDAN/A
Dividend YieldN/A
Koershistorie
Financiële Trends
Sectorvergelijking
vs Manufacturing sector mediaan (1364 peers)
Sectorvergelijking
vs Manufacturing sector mediaan (1364 peers)| Metriek | Aandeel | Sector Mediaan |
|---|---|---|
| P/E | -1,4 | -1,5 |
| P/B | 1,3 | 1,6 |
| ROE % | -91,4 | -53,4 |
| Net Margin % | — | -41,5 |
| Rev Growth 5Y % | — | 1,8 |
| D/E | — | 0,3 |
All Fundamental Metrics
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | N/A | Revenue Growth (3Y) | N/A |
| Earnings Growth (1Y) | N/A | Earnings Growth (3Y) | N/A |
| Revenue Growth (5Y) | N/A | Earnings Growth (5Y) | N/A |
| Profitability | |||
| Revenue (TTM) | N/A | Net Income (TTM) | -9,00 M |
| ROE | -91,39% | ROA | -70,07% |
| Gross Margin | N/A | Operating Margin | N/A |
| Net Margin | N/A | Free Cash Flow (TTM) | -11,13 M |
| ROIC | -887,68% | FCF Growth (3Y) | N/A |
| Safety | |||
| Debt / Equity | N/A | Current Ratio | 7,42 |
| Interest Coverage | N/A | Asset Turnover | N/A |
| Working Capital | 9,18 M | Tangible Book Value | 9,70 M |
| Dividends | |||
| Dividend Yield | N/A | Payout Ratio | N/A |
| Dividend Growth (3Y) | N/A | Dividend Growth (5Y) | N/A |
| Consecutive Div Years | N/A | ||
| Valuation | |||
| P/E Ratio | -1,35 | Forward P/E | N/A |
| P/B Ratio | 1,25 | P/S Ratio | N/A |
| PEG Ratio | N/A | Forward PEG | N/A |
| EV/EBITDA | N/A | Fwd EV/EBITDA | N/A |
| Forward P/S | N/A | Fwd Earnings Yield | N/A |
| FCF Yield | -91,76% | ||
| Market Cap | 12,13 M | Enterprise Value | 6,68 M |
| Per Share | |||
| EPS (Diluted TTM) | 0,02 | Revenue / Share | N/A |
| FCF / Share | -1,55 | OCF / Share | -1,55 |
| EPS CAGR (1Y) | -53,85% | EPS CAGR (5Y) | N/A |
| EPS CAGR (10Y) | N/A | ||
| Efficiency | |||
| CapEx / Revenue | N/A | FCF Conversion | 123,77% |
| SBC-Adj. FCF | -12,86 M | Growth Momentum | N/A |
Income Statement
Annual, most recent first
Income Statement
Annual, most recent first| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Net Income | -9,00 M | -13,95 M | -24,22 M | -27,65 M | -12,48 M |
| EPS (Diluted) | 0,02 | 0,04 | 0,10 | 0,12 | — |
| Gross Profit | — | — | — | — | — |
| Operating Income | -112,00 M | -103,00 M | — | — | — |
| EBITDA | — | — | — | — | — |
| R&D Expenses | 5,83 M | 11,33 M | 18,38 M | 16,98 M | 6,33 M |
| SG&A Expenses | — | — | — | — | — |
| D&A | — | — | — | — | — |
| Interest Expense | — | — | — | — | — |
| Income Tax | 0,0 | 0,0 | 0,0 | -534.000,0 | — |
Balance Sheet
Annual, most recent first
Balance Sheet
Annual, most recent first| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total Assets | 13,81 M | 16,96 M | 22,15 M | 43,06 M | 64,35 M |
| Total Liabilities | 1,48 M | 3,43 M | 5,15 M | 6,84 M | 2,89 M |
| Shareholders' Equity | 12,33 M | 13,54 M | 17,00 M | 36,22 M | 61,47 M |
| Total Debt | — | — | — | — | — |
| Cash & Equivalents | 7,56 M | 6,07 M | 9,29 M | 13,52 M | 15,19 M |
| Current Assets | 13,43 M | 16,04 M | 20,90 M | 41,74 M | 62,69 M |
| Current Liabilities | 1,48 M | 3,22 M | 4,84 M | 6,75 M | 2,65 M |
{"event":"ticker_viewed","properties":{"ticker":"CMMB","listing_kind":"stock","pathname":"/stocks/cmmb","exchange":"Nasdaq","country":"US"}}